CHEST Journal Podcasts

May 2026 CHEST Journal Editor Highlights

CHEST May 2026, Volume 169, Issue 5

CHEST® journal's Editor in Chief Peter Mazzone, MD, MPH, FCCP, highlights key research published in the journal CHEST May 2026 issue, including an analysis of interactive pathways of key prognostic factors in severe asthma, an investigation of the long-term safety and efficacy of proximal hypoglossal nerve stimulation in OSA, and more. 

Moderator:    
Peter Mazzone, MD, MPH, FCCP

Exacerbation Risk by Chronic Proton Pump Inhibitor Use in Obstructive Lung Diseases

Valerie Dehondt, PharmD, and Lies Lahousse, PharmD, PhD, join CHEST® Journal Podcast Moderator Gretchen Winter, MD, to discuss their research into the association between long-term proton pump inhibitor use and exacerbation risk in patients with chronic obstructive airway diseases.   

DOI: 10.1016/j.chest.2026.01.002

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.  

Pseudomonas aeruginosa in Patients With Nosocomial Respiratory Infections: A Secondary Analysis of the European Network for ICU-Related Respiratory Infections

Luis F. Reyes, MD, PhD, joins CHEST® Journal Podcast Moderator Matt Siuba, DO, MS, to discuss his research into the prevalence of Pseudomonas aeruginosa among patients with nosocomial respiratory infections in the ICU.

DOI: 10.1016/j.chest.2025.12.033

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.  

April 2026 CHEST Journal Editor Highlights

CHEST April 2026, Volume 169, Issue 4

CHEST® journal's Editor in Chief Peter Mazzone, MD, MPH, FCCP, highlights key research published in the journal CHEST April 2026 issue, including an exploration of inspiratory effort and dynamic transpulmonary driving pressure in extremely preterm infants undergoing noninvasive ventilation, an investigation of comparative outcomes and side effects of immunosuppressants and tumor necrosis factor inhibitors in sarcoidosis, and more.  

Moderator:    
Peter Mazzone, MD, MPH, FCCP

Use of and Outcomes Related to Intrapleural Enzyme Therapy for Complicated Parapneumonic Effusion and Empyema in an Integrated Health System

Eduardo Solbes, MD, joins CHEST® Journal Podcast Moderator Matt Siuba, DO, MS, to discuss his research into the variation in full MIST2 regimen dosing of intrapleural enzyme therapy across 21 hospitals in adults hospitalized with complicated parapneumonic effusion of empyema.  

DOI: 10.1016/j.chest.2025.11.042

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

March 2026 CHEST Journal Editor Highlights

CHEST March 2026, Volume 169, Issue 3      

CHEST® journal's Editor in Chief Peter Mazzone, MD, MPH, FCCP, highlights key research published in the journal CHEST March 2026 issue, including an investigation into a specialist dietary intervention in patients with fibrotic interstitial lung disease experiencing weight loss, an examination of the impact of dual cannabis and tobacco smoking in young patients with lung cancer, and more. 

Moderator:    
Peter Mazzone, MD, MPH, FCCP

Adjunctive Corticosteroid Use and Clinical Outcomes in Non-HIV Pneumocystis jirovecii Pneumonia

Aaron M. Pulsipher, MD, joins CHEST® Journal Podcast Moderator Matt Siuba, DO, MS, to discuss his research into the dose-response relationship between adjunctive corticosteroids and outcomes in adult patients with non-HIV Pneumocystis jirovecii pneumonia. 

DOI: 10.1016/j.chest.2025.10.036

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

CHEST Critical Care: The Impact of Mechanical Power Normalized to Predicted Body Weight on Outcomes in Pediatric ARDS

Authors Herng Lee Tan, MSc, and Judith Ju Ming Wong, MBBCh, BAO, and editorialist Vicent Modesto i Alapont, MD, PhD, join CHEST® Critical Care Podcast Moderator Dan Fein, MD, to discuss their research into the impact of mechanical power normalized to predicted body weight on outcomes in pediatric ARDS. 

This episode is part of a new series exploring articles published in our open access journal CHEST Critical Care. 

DOI: 10.1016/j.chstcc.2025.100162

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.  

February 2026 CHEST Journal Editor Highlights

CHEST February 2026, Volume 169, Issue 2      

CHEST® journal's Editor in Chief Peter Mazzone, MD, MPH, FCCP, highlights key research published in the journal CHEST February 2026 issue, including an examination of the association between culture conversion and mortality in patients with Mycobacterium abscessus complex pulmonary disease, an investigation of the comparative effectiveness of tocilizumab vs rituximab in rheumatoid arthritis-associated interstitial lung disease, and more.    

Moderator:    
Peter Mazzone, MD, MPH, FCCP

Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial

James Cheng Chung Wei, MD, PhD, and Po-Cheng Shih, MD, join CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss their research into the comparative effectiveness and safety of tocilizumab and rituximab in patients with rheumatoid arthritis-associated interstitial lung disease.  

DOI: 10.1016/j.chest.2025.09.009

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.